Elezanumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Elezanumab (ABT-555; AE12-1Y-QL) 是一种人单克隆抗体，可选择性靶向排斥性引导分子 A (RGMa)。Elezanumab 通过 SMAD1/5/8 通路有效抑制 RGMa 介导的 BMP 信号传导，IC50 约为 97 pM。Elezanumab 促进神经元损伤和脱髓鞘模型中的神经再生和神经保护作用，可结合 N 末端 RGMa、阻断 BMP 信号传导并缺乏 RGMc 交叉反应性。Elezanumab 具有神经再生和神经保护活性，对铁代谢没有影响。

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.

——

Animal Model:Female Lewis rat optic neuritis modelsDosage:1, 3, or 10 mg/kg Administration:IV; once a week for 5 doses Result:Protected against the optic nerve inflammationinduced RNFL degeneration.Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg

——

Others

Other Targets

TGF-beta/Smad

——

——

1791416-49-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years